Chinese heparin maker tried to sneak proof of its unapproved APIs out the back door

pointing finger
The FDA has issued an import alert for all of the products coming out of the plant of Chinese API maker, Yibin Lihao Bio-technical, including its crude heparin. (Pixabay)

On arrival for a pre-approval inspection for a Chinese heparin API maker, an FDA inspector was told that the plant had not started making products and was only doing equipment testing. The truth of the matter was hidden in a drum being snuck out the back. An intercepted container an employee was removing from the warehouse contained two batches of crude heparin manufactured two days earlier. 

That was just the beginning of the problems found during July 2019 inspection of Yibin Lihao Bio-technical, the API maker in Yibin city of Sichuan province, China. According to a warning letter, there were quality assurance records scattered in cabinets, on desks and on the floor of the QA office. Employees insisted they were for a grant application from the government and not manufactured products. Not true. The FDA would learn the records did correspond to manufactured heparin. 

RELATED: Chinese heparin maker banned by EMA over contamination risks

Free Webinar

Building a Flexible, Challenge Resistant and Patient Centric Clinical Supply Chain

The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. In this webinar, learn the benefits of utilizing demand-led supply and direct-to-patient distribution models in the clinical supply chain, as well as how they can be used to both improve flexibility and better align with patient needs. Register today!

The FDA last month placed Lihao Bio-technical on import alert, banning its crude heparin and other products from the U.S., in part because its “system for managing quality is inadequate and calls into question the traceability of all drugs, including crude heparin manufactured at your facility.”

Traceability of crude heparin and its raw ingredients has been a big issue at the FDA for a decade after it was whiplashed by Congressional leaders over tainted Chinese heparin in the U.S. supply used to make the finished blood thinner. The investigation began after heparin batches were tied to hundreds of allergic reactions, some fatal. 

RELATED: Congress hits panic button over potential Chinese heparin shortage as swine herds ravaged by disease 

More recently, Congress has been concerned over the U.S. getting adequate supplies of heparin. Crude heparin is made from pig intestines and China’s swine herds have been devastated by disease. Adding to that is the chance of supply interruptions from COVID-19 

Yibin Lihao Bio-technical won’t be supplying any heparin API any time soon. In addition to banning its products, the FDA ordered the manufacturer to get its record-keeping in order and provide the FDA with a comprehensive investigation into the inaccuracies in its data reporting and the potential risks to patients from the drugs the firm has distributed to the U.S.

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.